Cargando…

Prognostic Factors for Postoperative Bleeding Complications and Prolonged Intensive Care after Percutaneous Hepatic Chemosaturation Procedures with Melphalan

SIMPLE SUMMARY: Percutaneous hepatic melphalan perfusion (chemosaturation) is a treatment option in patients with inoperable liver metastases which is associated with considerable procedural challenges, especially hemodynamic depression, due to a reduced preload and impaired coagulation caused by th...

Descripción completa

Detalles Bibliográficos
Autores principales: Struck, Manuel Florian, Werdehausen, Robert, Kirsten, Holger, Gössmann, Holger, Veelken, Rhea, van Bömmel, Florian, Stehr, Sebastian, Denecke, Timm, Ebel, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417144/
https://www.ncbi.nlm.nih.gov/pubmed/37568592
http://dx.doi.org/10.3390/cancers15153776
_version_ 1785087953412816896
author Struck, Manuel Florian
Werdehausen, Robert
Kirsten, Holger
Gössmann, Holger
Veelken, Rhea
van Bömmel, Florian
Stehr, Sebastian
Denecke, Timm
Ebel, Sebastian
author_facet Struck, Manuel Florian
Werdehausen, Robert
Kirsten, Holger
Gössmann, Holger
Veelken, Rhea
van Bömmel, Florian
Stehr, Sebastian
Denecke, Timm
Ebel, Sebastian
author_sort Struck, Manuel Florian
collection PubMed
description SIMPLE SUMMARY: Percutaneous hepatic melphalan perfusion (chemosaturation) is a treatment option in patients with inoperable liver metastases which is associated with considerable procedural challenges, especially hemodynamic depression, due to a reduced preload and impaired coagulation caused by the use of heparin. Studies on factors that contribute to bleeding complications and a prolonged intensive care unit length of stay are not available. In this retrospective analysis, we found that high perioperative infusion volumes and the omission of heparin reversal with protamine were associated with postoperative bleeding complications, while high infusion volumes also contributed to a length of stay in the intensive care unit of more than one day, which usually is not required. Furthermore, protamine use was not significantly associated with anaphylactic or thromboembolic complications. Our findings suggest a restrictive perioperative infusion regime and support the use of postoperative protamine for heparin reversal in chemosaturation procedures. ABSTRACT: Percutaneous hepatic melphalan perfusion (chemosaturation) in patients with liver metastases is known to be associated with procedure-related hemodynamic depression and coagulation impairment, which may cause bleeding complications and/or a prolonged intensive care unit length of stay (ICU LOS). We retrospectively analyzed possible predictive factors for bleeding complications and an ICU LOS > 1 d in a cohort of 31 patients undergoing 90 chemosaturation procedures. Using a multivariable mixed-model approach, we identified the amount of perioperative fluid volume (OR 12.0, 95% CI 2.3–60.0, p = 0.003) and protamine (OR 0.065, 95% CI 0.007–0.55, p = 0.012) to be associated with bleeding complications. Furthermore, the amount of perioperative fluid volume was associated with an ICU LOS > 1 d (OR 5.2, 95% CI 1.4–19.0, p = 0.011). Heparin dosage, melphalan dosage, extracorporeal circulation time, and noradrenaline dosage had no significant effects on outcomes. Protamine use was not associated with anaphylactic or thromboembolic complications. Despite the limited sample size, these results suggest a restrictive perioperative fluid regime to be beneficial, and support the use of protamine for heparin reversal after chemosaturation procedures. Further prospective randomized trials are needed to confirm these findings.
format Online
Article
Text
id pubmed-10417144
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104171442023-08-12 Prognostic Factors for Postoperative Bleeding Complications and Prolonged Intensive Care after Percutaneous Hepatic Chemosaturation Procedures with Melphalan Struck, Manuel Florian Werdehausen, Robert Kirsten, Holger Gössmann, Holger Veelken, Rhea van Bömmel, Florian Stehr, Sebastian Denecke, Timm Ebel, Sebastian Cancers (Basel) Article SIMPLE SUMMARY: Percutaneous hepatic melphalan perfusion (chemosaturation) is a treatment option in patients with inoperable liver metastases which is associated with considerable procedural challenges, especially hemodynamic depression, due to a reduced preload and impaired coagulation caused by the use of heparin. Studies on factors that contribute to bleeding complications and a prolonged intensive care unit length of stay are not available. In this retrospective analysis, we found that high perioperative infusion volumes and the omission of heparin reversal with protamine were associated with postoperative bleeding complications, while high infusion volumes also contributed to a length of stay in the intensive care unit of more than one day, which usually is not required. Furthermore, protamine use was not significantly associated with anaphylactic or thromboembolic complications. Our findings suggest a restrictive perioperative infusion regime and support the use of postoperative protamine for heparin reversal in chemosaturation procedures. ABSTRACT: Percutaneous hepatic melphalan perfusion (chemosaturation) in patients with liver metastases is known to be associated with procedure-related hemodynamic depression and coagulation impairment, which may cause bleeding complications and/or a prolonged intensive care unit length of stay (ICU LOS). We retrospectively analyzed possible predictive factors for bleeding complications and an ICU LOS > 1 d in a cohort of 31 patients undergoing 90 chemosaturation procedures. Using a multivariable mixed-model approach, we identified the amount of perioperative fluid volume (OR 12.0, 95% CI 2.3–60.0, p = 0.003) and protamine (OR 0.065, 95% CI 0.007–0.55, p = 0.012) to be associated with bleeding complications. Furthermore, the amount of perioperative fluid volume was associated with an ICU LOS > 1 d (OR 5.2, 95% CI 1.4–19.0, p = 0.011). Heparin dosage, melphalan dosage, extracorporeal circulation time, and noradrenaline dosage had no significant effects on outcomes. Protamine use was not associated with anaphylactic or thromboembolic complications. Despite the limited sample size, these results suggest a restrictive perioperative fluid regime to be beneficial, and support the use of protamine for heparin reversal after chemosaturation procedures. Further prospective randomized trials are needed to confirm these findings. MDPI 2023-07-25 /pmc/articles/PMC10417144/ /pubmed/37568592 http://dx.doi.org/10.3390/cancers15153776 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Struck, Manuel Florian
Werdehausen, Robert
Kirsten, Holger
Gössmann, Holger
Veelken, Rhea
van Bömmel, Florian
Stehr, Sebastian
Denecke, Timm
Ebel, Sebastian
Prognostic Factors for Postoperative Bleeding Complications and Prolonged Intensive Care after Percutaneous Hepatic Chemosaturation Procedures with Melphalan
title Prognostic Factors for Postoperative Bleeding Complications and Prolonged Intensive Care after Percutaneous Hepatic Chemosaturation Procedures with Melphalan
title_full Prognostic Factors for Postoperative Bleeding Complications and Prolonged Intensive Care after Percutaneous Hepatic Chemosaturation Procedures with Melphalan
title_fullStr Prognostic Factors for Postoperative Bleeding Complications and Prolonged Intensive Care after Percutaneous Hepatic Chemosaturation Procedures with Melphalan
title_full_unstemmed Prognostic Factors for Postoperative Bleeding Complications and Prolonged Intensive Care after Percutaneous Hepatic Chemosaturation Procedures with Melphalan
title_short Prognostic Factors for Postoperative Bleeding Complications and Prolonged Intensive Care after Percutaneous Hepatic Chemosaturation Procedures with Melphalan
title_sort prognostic factors for postoperative bleeding complications and prolonged intensive care after percutaneous hepatic chemosaturation procedures with melphalan
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417144/
https://www.ncbi.nlm.nih.gov/pubmed/37568592
http://dx.doi.org/10.3390/cancers15153776
work_keys_str_mv AT struckmanuelflorian prognosticfactorsforpostoperativebleedingcomplicationsandprolongedintensivecareafterpercutaneoushepaticchemosaturationprocedureswithmelphalan
AT werdehausenrobert prognosticfactorsforpostoperativebleedingcomplicationsandprolongedintensivecareafterpercutaneoushepaticchemosaturationprocedureswithmelphalan
AT kirstenholger prognosticfactorsforpostoperativebleedingcomplicationsandprolongedintensivecareafterpercutaneoushepaticchemosaturationprocedureswithmelphalan
AT gossmannholger prognosticfactorsforpostoperativebleedingcomplicationsandprolongedintensivecareafterpercutaneoushepaticchemosaturationprocedureswithmelphalan
AT veelkenrhea prognosticfactorsforpostoperativebleedingcomplicationsandprolongedintensivecareafterpercutaneoushepaticchemosaturationprocedureswithmelphalan
AT vanbommelflorian prognosticfactorsforpostoperativebleedingcomplicationsandprolongedintensivecareafterpercutaneoushepaticchemosaturationprocedureswithmelphalan
AT stehrsebastian prognosticfactorsforpostoperativebleedingcomplicationsandprolongedintensivecareafterpercutaneoushepaticchemosaturationprocedureswithmelphalan
AT denecketimm prognosticfactorsforpostoperativebleedingcomplicationsandprolongedintensivecareafterpercutaneoushepaticchemosaturationprocedureswithmelphalan
AT ebelsebastian prognosticfactorsforpostoperativebleedingcomplicationsandprolongedintensivecareafterpercutaneoushepaticchemosaturationprocedureswithmelphalan